7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans.

      Nature medicine
      Animals, Anti-Arrhythmia Agents, therapeutic use, Arrhythmias, Cardiac, prevention & control, Calcium, physiology, Child, Flecainide, Heart Rate, drug effects, Humans, Male, Mice, Polymorphism, Genetic, Ryanodine Receptor Calcium Release Channel, Syndrome, Tachycardia, Ventricular, genetics

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal inherited arrhythmia syndrome in which drug therapy is often ineffective. We discovered that flecainide prevents arrhythmias in a mouse model of CPVT by inhibiting cardiac ryanodine receptor-mediated Ca(2+) release and thereby directly targeting the underlying molecular defect. Flecainide completely prevented CPVT in two human subjects who had remained highly symptomatic on conventional drug therapy, indicating that this currently available drug is a promising mechanism-based therapy for CPVT.

          Related collections

          Author and article information

          Comments

          Comment on this article